a Blue chip investor and micro cap trader.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Should I stay, or should I go?"
Same old song....ROFLMAO
As they say: TO THE MOON
but what do they know that we do not?
Is CLRB part of Biden''s Moon Shot to cure cancer???
$2 or $3 here we come,
On the way to $7 for first TARGET....yippee !
OR SO IT SEEMS....
FILM AT "eleven" on nightly news....LOL
IT IS JUST NEWS:
https://finance.yahoo.com/news/cellectar-biosciences-announces-additional-us-133000688.html
The time is ripe for accumulation of CRRB, because the results of the final 2 cohorts of Phase 1 clinical trials will be on the table very soon and the promised Phase 2 clinical trial will be started next month.
"...Premarket Gainers / Losers as of 9:10 am
Jan. 24, 2017 9:14 AM ET|By:
Gainers: MPSX +24%. CLRB +18%. IDXG +17%. NAK +11%. RMD +9%. MRCY +8%. FOLD +8%. AKS +8%. GPRO +5%.
Losers: BT -20%. BIOA -14%. GLOP -8%. FSM -8%. OCUL -7%.DRYS -6%. CASC -5%. GLBS -5%...."
Accumulation seems to be starting...
The time is ripe for accumulation of CRRB, because the results of the final 2 cohorts of Phase 1 clinical trials will be on the table very soon and the promised Phase 2 clinical trial will be started next month.
The point of recognition will be when the market realizes that CLRB has a few patented miracle drugs .
Lives will be saved! And without the poison of chemotherapy,
Son of Wolf, the boy who cried wolf, will eventually make you rich on "the rest"....eventually....
CLRB Takes Awhile...
So consider MJNA FOR SOMETHING QUICKER and gratifying! LOL
Watch the price action tomorrow,
See if the first hour+ are bullish again!
It was a great presentation, revealing
much, such as CT 2 enlisting now and CT1 having a 4th cohort at higher does of radioactive iodine in 2nd & 3rd Quarters 2017. They are pressing forward with over 13 million dollars in reserves. This is the schedule from today's slide presentation at conference in SF:
https://cache.webcasts.com/content/gwgg002/1130827/content/d8dc8630200b4a8e9a89a6cc2cfe635882a9f55d/html5/data/pres/s28s2.jpg
Flippers front loaded today's conference presentation, hoping CLRB would pump and they could dump.
But CLRB is using standard scientific method to develop products, not pump & dump.
The smart money is buying the dips and holding accumulation, IMHO.
There are flippers in size here,
But underlying accumulation is in progress. Flippers work at any price level until this stock goes ballistic.
GLTAL
Accumulation seems to be starting...
The time is ripe for accumulation of CRRB, because the results of the final 2 cohorts of Phase 1 clinical trials will be on the table very soon and the promised Phase 2 clinical trial will be started next month.
The point of recognition will be when the market realizes that CLRB has a few patented miracle drugs .
Lives will be saved! And without the poison of chemotherapy,
http://www.nasdaq.com/press-release/cellectar-biosciences-announces-results-from-the-first-two-cohorts-of-its-clr-131-phase-1-trial-20161201-00411
Accumulation seems to be starting...
So Happy New Year!
Accumulation seems to be starting...
So Happy New Year!
Buying the dips,
bottom fishing.
Tonight 6-8 pm PT in San Diego,
but I doubt that they will go much beyond the Abstract that I posted below which includes data up to 6-30-16.
It would be great if the presenters gave some hints about the last 5 months, but it is not the scientific way. I am confident this technology works well and will sell well to desperate MM patients. It will likely give over a year of life to spend with family and friends. It will sell for about $100,000 a treatment. Would you and your health insurance pay that much to live an extra year or two? I would.
But, it seems we need another 6 months to let the genie out of the bottle. However, the stock market reacts about 6 months ahead of the news.
N.B.: Abstract data posted below
IS ONLY PRESENTED THROUGH JUNE 30, 2016, MORE THAN 5 MONTHS AGO!
PFS COULD BE 8 MONTHS OR MUCH LONGER!
CLR131 could be the way to make MM a chronic disease, not a fatal one as it is now- more or less. IMHO
So it will be interesting to see if there is an update about the last 5 months data results on the ORAL PRESENTATION TOMORROW EVENING.
"I don't know, but it is looking good so far!" (Top Gun Movie)
ABSTRACT OF TOMORROW NIGHT's PRESENTATION:
Note this statement in the abstract below: "...Stable disease was achieved in 100% of evaluable patients..".
DOES THIS CHANGE EVERYTHING FOR US?IT SURE LOOKS LIKE IT!
From the San Diego ASH CONFERENCE website:
"4485 Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Myeloma: Therapy, excluding Transplantation
Program: Oral and Poster Abstracts
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster III
Monday, December 5, 2016, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
Sikander Ailawadhi, MD1, Patrick J. Stiff, MD2, Michele Maharaj, RN, OCN, CCRP3*, Katherine Oliver, BS, CCRP4* and Natalie Scott Callander, MD5
1Division of Hematology, Mayo Clinic, Jacksonville, FL
2Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL
3Mayo Clinic Florida, Jacksonville, FL
4Cellectar Biosciences, Madison, WI
5University of Wisconsin Carbone Cancer Center, Madison, WI
Background: I-131-CLR1404 is a novel radioiodinated therapeutic that exploits the selective uptake and retention of phospholipid ethers (PLEs) by malignant cells. Based on initial preclinical and clinical experience and the exquisite radiosensitivity of MM, I-131-CLR1404 is being examined in RRMM in an open-label, dose escalation Phase 1 trial (NCT02278315) evaluating up to 5 cohorts and a maximum of 37.5 mCi/m2.
Methods: The primary objective is to determine safety and tolerability of I-131-CLR1404 with and without dexamethasone (dex) in RRMM. Secondary objectives are to determine the recommended Phase 2 dose (RP2D) and therapeutic activity in RRMM. Eligibility criteria include progressive, relapsed/refractory MM, and at least one previous exposure to proteasome inhibitor (PI) and immunomodulatory (IMiD) drugs. Prior autologous stem cell transplant (ASCT) and external beam radiation therapy are allowed (≤ 20% of total marrow irradiated). There is no limit to the number of prior therapies. I-131-CLR1404 is administered intravenously as a single 30 minute infusion on day 1 with 40 mg dex orally weekly for 12 weeks. Dose-escalation uses a minimally modified, standard 3+3 schema with dose-limiting toxicities (DLTs) assessed through day 85 post-infusion. Adverse events (AEs) are graded by NCI-CTCAE v4.03; responses are assessed by the International Myeloma Working Group Uniform Response Criteria.
Results: Ten patients have been enrolled in the study with data presented as of 30 Jun 2016 for 8 patients. Accrual is ongoing in the additional cohorts. Five patients were enrolled to cohort 1 (12.5 mCi/m2 + dex); 4 were evaluable and 1 patient was taken off study for rapid disease progression. Five patients have been enrolled to cohort 2 (18.75 mCi/m2 + dex), with data presented on 3 enrolled prior to data cutoff. The median age was 68.5 (range 55-85) and included 5 males and 3 females. All patients were standard risk (karyotyping) and median bone marrow plasma cell involvement was 25% (range 4-50%). Median number of prior therapies was 4 (range 2-12) (Table 1). Four of 8 patients previously underwent ASCT and 25% were previously treated with radiation therapy. Hematologic AEs (grade 3+) and non-hematologic AEs (grade 2+) potentially related to study drug are shown in Table 1. No difference in the toxicity profile was noted for patients with previous radiation therapy. Two serious adverse events (SAEs) have been reported, both in patients treated with 18.75 mCi/m2 I-131-CLR1404. One patient was hospitalized for a seizure (Day 62), assessed as unrelated to study drug and another patient was hospitalized for a grade 1 upper GI bleed in the setting of grade 4 thrombocytopenia (Day 23). This is believed to be the result of rapidly progressive disease, however relationship to I-131-CLR1404 could not be ruled out.
Stable disease was achieved in 100% of evaluable patients (n=7). One subject in cohort 1 demonstrated a > 30% reduction in serum m-protein. Figure 1 provides a summary of percent change in serum free light chain assay (FLC) from baseline. Three patients had a reduction in FLC > 50%, 2 in cohort 1 and 1, to date, in cohort 2. Three patients had a stable FLC response through at least 22 days following treatment and 1 subject was unresponsive with regard to FLC. Median follow-up is 6.8 months (range 1.2-14.2). Patients did not receive subsequent systemic therapy for a median of 3.5 months (range 0.6-4.7). Furthermore, 1 subject in cohort 2 maintains stable disease and has not initiated subsequent treatment. Median progression free survival (PFS) is 3 months and included 4 patients with stable disease at the end of the 85 day study follow-up. In patients with progression after I-131-CLR1404, treatment included daratumumab (n=4), ASCT (n=1), and bortezomib, lenalidomide, and dex (VRD) (n=1).
Conclusions: I-131-CLR1404 represents a unique, first in class targeted radiotherapeutic for MM. Preliminary data from this trial show an acceptable and expected safety profile with an efficacy signal in the initial 2 of a potential 5 cohorts. All evaluable patients, despite extensive previous therapy and refractoriness to new therapies, achieved disease stabilization. The study is ongoing to determine the RP2D and long term efficacy."
NO WONDER THE UNIVERSITY ALUMNAI FUND IS DONATING ANOTHER 12 MILLION DOLLARS TO CLRB. THEY OWN 600,000 SHARES OF COMON STOCK IN CLRB?
Going under radar until Monday:
The market knows everything, and it is going against me now.
Unless Monday changes EVERYTHING, this is a dead money stock!
Over & out!
One million shares traded today: newly minted ones?
Ya gotta keep 'em separated!
By the time you hear the siren, it already too late...
From today's CLR 131 news:
"...At this time, Cohort 1 and Cohort 2 patients have demonstrated post treatment median survival of 11.9 months and 4.9 months, respectively. The median survival for all evaluable patients in both cohorts continues to increase and will be followed to determine overall survival benefit. Currently, the median overall survival (mOS) for each cohort is not yet evaluable..."
GET IT? Median survival "CONTINUES TO INCREASE". GET IT?
THEY ARE STILL ALIVE, MS. MARKET!!!
(Put that in your pipe and smoke it!)b
Sun: It's the biggest casino in the world,
look at all the shorts in crude oil 2 days ago. Killed!
The spike up to $1.90 in today's pre-market trading was on the press release this morning. The casino took their money on the open. Place your bets folks.
http://www.nasdaq.com/symbol/clrb/short-interest
time to place your bets!
Today's NEWS:
Cohorts 1 & 2 of Phase 1:
http://www.streetinsider.com/dr/news.php?id=12300419
MONDAY WE GET PHASE ONE COHORT THREE DATA AT THE HIGHEST DOSES OF RADIOACTIVE IODINE SO FAR. IT WILL BE "MAKE OR BREAK TIME" NEXT MONDAY, KIDS! "PAYS YOU's MONEY AND TAKE YER CHANCES"!
http://www.nasdaq.com/symbol/clrb/short-interest
There are shorts and longs. They make it interesting, like Monday's crude oil shorts!
sub360: wait for dose escalation data:
The third cohort of phase one trial will please EVERYONE!
It pleased the latest trial patients, IMHO.
We expect significant data on clinical trials:
http://investor.cellectar.com/releasedetail.cfm?releaseid=994996
CLRB LONG TERM TARGET: $60 pps
http://www.cnbc.com/2016/12/01/bluebird-celgene-myeloma-treatment-impresses-in-tiny-study.html
Same stage of trials with small number of patients, same lack of side effects concern, same disease target as CLR131, but with backing of Big Pharma- Celegene.
CLRB, one of these days, CLRB MAKES A SHORT TERM TARGET RUN TO $10 IMHO. AND IT COULD BE NEXT MONDAY WHEN THE PHASE ONE RESULTS ARE RELEASED FOR CLR 131!!!
WE JUST NEED A BIG PHARMA PARTNER OR SUITER FROM BIG PHARMA!
I agree! eom
Will this ever help CLRB?
The U.S. House of Representatives on Wednesday passed a sweeping, $6.3 billion bill that supporters say will spur medical innovation, speed access to new drugs, expand access to mental health treatment and battle the opioid epidemic.
The bill, known as the 21st Century Cures Act, had widespread bipartisan support, including the backing of the Obama administration, though critics said it gives massive handouts to the pharmaceutical industry while making cuts to public health programs and Medicare.
Sunofwolf: from Insider monkey on big time investors:
"...None of the 742 funds tracked by Insider Monkey which filed 13Fs for the September quarter were long Cellectar Biosciences Inc (NASDAQ:CLRB) at the end of the third quarter..."
Yes, but on the other hand:
"...Gross offering proceeds to the company, including the exercise of the $1.2 million over-allotment option, are $9.2 million, while net proceeds, after deducting underwriting discounts, commissions and offering expenses, are estimated to be approximately $8.3 million. The company anticipates that these (net) proceeds will be sufficient to fund operations into the first quarter of 2018..." (Emphasis added)
CLRB LIVES FOR ANOTHER 14 MONTHS TO PROVE IT IS A LIFE SAVING TECHNOLOGY THAT DOES NOT KILL MANY MORE HEALTHY CELLS THAN BLOOD CANCER CELLS. TRY VISITING A CANCER TREATMENT CENTER NEAR YOU AND SEE THE BALD AND PALE PEOPLE BEING POISONED TO DEATH BY STANDARD CHEMOTHERAPY. IT IS HORRIBLE.
CLRB IS A KNOCK DOWN THE DOORS PREFERABLE TARGETED ALTERNATIVE- IF THE DELIVERY CHEMICAL IS EFFECTIVE ON ONLY OR MOSTLY ON CANCER CELLS. IF YOU ARE TOLD "YOUR MONEY OR YOUR LIFE" BY YOUR HIGHWAYMAN DOCTOR, WHAT WOULD YOU DO???
VERY SAD BUT TRUE!
Sun: Interesting observations! eom
anderbest18: the Phase 1 news has been fair,
as CLRB has been upping the dose of radioactive material for targeted delivery. But the cohorts in Phase 1 have been small, so in that sense the news has been disappointing. On the other hand, there has been no JUNO type really bed side effect news with patients quickly dying in the trials.
I would say the jury is still out until 12-5-16 on Phase 1 results.
Outstanding analysis there, Hypothetically!
I have been buying CLRBW & CLRBZ as a hedge too.
But your business sense is most interesting on those reasons.
Wish we privately knew why
...It doesn't' seem to want to go up?!
Engaging CPDC, a Canadian Company, was smart!
Considering how US drug manufactures and distributors screw consumers in the USA with drug prices compared to foreign prices for the same drugs, CLRB's product lines will quickly become global products in demand everywhere- economy of scale and patient friendly distribution will offset outrageous prices that limit demand.
http://ih.advfn.com/p.php?pid=nmona&article=73011827&symbol=CLRB
Also, see this article from The Economist:
http://www.economist.com/blogs/democracyinamerica/2015/06/pharmaceutical-pricing
"...This problem of sky-rocketing costs for questionable drugs has festered in America for several reasons. First, pharmaceutical companies can advertise directly to patients in America, which helps ensure demand. Second, price increases have been largely invisible to both patients and their doctors, in part because health-insurance plans often shield buyers from the true costs of their drugs. Third, Medicare, the public-health programme for those aged 65 and older, is the country’s largest drug customer, yet it is not allowed to negotiate prices with drug companies—with predictable results..."
Yes, but market does not acknowledge this:
https://finance.yahoo.com/news/cellectar-biosciences-announces-partnership-radiopharmaceutical-130000456.html
It seems very clear to me that there is very good news coming on 12-5-16 about CLR131 in Phase 1 trial results, but the market does not want to acknowledge this yet.
SO STRANGE THAT THE MARKET SELLS OFF EACH TIME THERE IS REASON TO BUY SHARES. THERE ARE ONLY TWO EXPLANATIONS FOR THIS BEHAVIOR!
AND I AM ONLY SMART ENOUGH TO UNDERSTAND ONE OF THEM- MARKET MANIPULATION BY SHORTY.
Jeff: Much more of the same next week,
When'd the funds and bigger money wake up to what is happening here.
CLRB IS SAVING LIVES WITH ITS UNIQUE DELIVERY PLATFORM ON TARGETS ONLY!
Now that THE BOTTOM is in,
I watch with interest the CLRB price chart going into 12-5-2016**.
This is going to be a HAPPY RIDE, and we can expect all new screen names to dominate this board.
I welcome the excitement and all the new front runners!
** Cellectar Biosciences, Inc. (NASDAQ:CLRB) announces that it will be presenting data from its Phase 1 clinical trial of CLR 131 in relapsed or refractory multiple myeloma at a poster session of the American Society of Hematology Meeting and Exposition in San Diego. Poster: #4485, “Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)” Presenter: Sikander Ailawadhi, MD, vice chair, clinical practice, Division of Hematology/Oncology, Department of Medicine at the Mayo Clinic, Florida,Session/Date/Time: #653 – “Myeloma: Therapy, Excluding Transplantation,” December 5, 2016, 6:00pm – 8:00pm PT Location: San Diego Convention Center in Hall GH
Hummm...a 40 bagger
and I was hoping for just a 10 bagger...
gink: or to be more specific,
These warrants work as cheap leverage:
Cellectar Biosciences Announces Closing of Public Offering and Partial Exercise of Underwriter's Over-Allotment Option
MADISON, Wis., Aug. 20, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced the closing of an underwritten public offering of 3,333,333 shares of its common stock at a per share price of $3.75 and warrants to purchase up to the same number of shares of common stock at a per warrant price of $0.01; plus the issuance of approximately an additional 1,110,000 shares and warrants in consideration of the cancellation of $4,000,000 principal amount of convertible debentures plus accrued interest. The warrants have an exercise price of $4.68 per share, are immediately exercisable and expire in August 2019.
The Company also announced today that the underwriter partially exercised the over-allotment option to purchase an additional 250,000 shares of common stock and acquired warrants to purchase 500,000 shares of common stock. The underwriter also has a 45-day option to purchase up to an additional 250,000 shares of common stock to cover additional over-allotments, if any. Including tender of all outstanding convertible debentures, the company is offering a total of approximately 4,700,000 common shares and approximately 5,000,000 warrants.
The gross proceeds to the Company, including the underwriter's partial exercise of the over-allotment option, were $13,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.
The shares and warrants began trading on the NASDAQ Capital Market on August 15, 2014 under the symbols "CLRB" and "CLRBW," respectively.
Aegis Capital Corp acted as the sole book-running manager for the offering.
A registration statement on Form S-1 relating to the shares and warrants was filed with the U.S. Securities and Exchange Commission (the "SEC") and was declared effective on August 14, 2014. A final prospectus relating to the offering has been filed with the SEC and is available, for free, on the SEC's website at http://www.sec.gov. Copies of the final prospectus relating to the offering may be obtained from the offices of Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com, or from the above-mentioned SEC website.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities, in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
Warrants are in many ways similar to options, but a few key differences distinguish them. Warrants are generally issued by the company itself, not a third party, and they are traded over-the-counter more often than on an exchange. Investors cannot write warrants like they can options. Unlike options (with the exception of employee stock options), warrants are dilutive: when an investor exercises her warrant, she receives newly issued stock, rather than already-outstanding stock. Warrants tend to have much longer periods between issue and expiration than options, of years rather than months.
Warrants do not pay dividends or come with voting rights. Investors are attracted to warrants as a means of leveraging their positions in a security, hedging against downside (for example, by combining a put warrant with a long position in the underlying stock) or exploiting arbitrage opportunities.
Warrants are no longer very common in the U.S., but are heavily traded in Hong Kong, Germany and other countries.
Types Of Warrants
Traditional warrants are issued in conjunction with bonds, which in turn are called warrant-linked bonds, as a kind of sweetener that allows the issuer to offer a lower coupon rate. These warrants are often detachable, meaning that they can be separated from the bond and sold on the secondary markets before expiration. A detachable warrant can also be issued in conjunction with preferred stock; often the warrant must be sold before the investor can collect dividends.
Wedded or wedding warrants are not detachable, and the investor must surrender the bond or preferred stock the warrant is "wedded" to in order to exercise it. Naked warrants are issued on their own, without accompanying bonds or preferred stock.
Covered warrants are issued by financial institutions rather than companies, so no new stock is issued when covered warrants are exercised. Rather, the warrants are "covered" in that the issuing institution already owns the underlying shares or can somehow acquire them. The underlying securities are not limited to equity, as with other types of warrants, but may be currencies, commodities or any number of other financial instruments.
Trading Warrants
Trading warrants can be difficult and time-consuming, as they are for the most part not listed on stock exchanges, and data on warrant issues is not readily available for free. When a warrant is listed on an exchange, its ticker symbol will often be the symbol of the company's common stock with a W added to the end. For example, Abeona Therapeutics Inc's (ABEO) warrants are listed on Nasdaq under the symbol ABEOW. In other cases, a Z will be added, or a letter denoting the specific issue (A, B, C…).
Warrants generally trade at a premium, which is subject to time decay as the expiration date nears. As with options, warrants can be priced using the Black-Scholes model.
Read more: Warrant Definition | Investopedia http://www.investopedia.com/terms/w/warrant.asp#ixzz4QrlcJxkm
Follow us: Investopedia on Facebook
BEEN BUYING thousands of CLRB IN 1.40's
and sure hope it pays off after 12-5-16.
Also bought thousands of CLRBW warrants in the .20's